Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

Am­gen is mov­ing for­ward with the launch of Pavblu, its biosim­i­lar to Re­gen­eron’s block­buster Eylea, fol­low­ing an ap­peals court de­ci­sion that ruled against com­peti­tor Re­gen­eron …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER